Skip to main content
. 2022 Jun 28;14(13):3155. doi: 10.3390/cancers14133155

Table 1.

Baseline characteristics of the HS group population.

Variables HS (n = 96)
Gender, male/female, n (%) 58 (60)/38 (40)
Age(year), Mean ± SD 54 ± 9
Etiology, HBV/HCV/alcohol or others, n (%) 76 (79)/14 (15)/6 (6)
History of HCC treatment, yes/no, n (%) 22 (23)/74 (77)
Preoperative anti-viral therapy, yes/no, n (%) 56 (58)/40 (42)
Varices hemorrhage, yes/no, n (%) 43 (45)/53 (55)
WBC (×109/L), Median (IQR) 2.3 (1.8, 3.4)
HGB (g/L), Median (IQR) 114.5 (88, 134.2)
PLT (×109/L), Median (IQR) 47 (37, 65.2)
ALT (U/L), Median (IQR) 28.5 (19, 41)
Tbil (umol/L), Median (IQR) 21 (15.3, 28.7)
Albumin (g/L), Mean ± SD 36.1 ± 5.4
Child-Pugh score, n (%)
5 33 (34)
6 36 (38)
7 17 (18)
8 8 (8)
9 2 (2)
AFP (ng/mL), Median (IQR) 23.7 (3.4, 234.2)
PTA (%), Mean ± SD 72.5 ± 12.7
Fibroscan (Kpa), Median (IQR) 20.9 (14.5, 27.2)
Tumor diameter (mm), Median (IQR) 24 (14, 39.2)
Tumor number, 1/2/3, n (%) 82 (85)/10 (10)/4 (4)
Tumor stage, 1/2/3, n (%) 48 (50)/39 (41)/9 (9)
Vascular invasion, yes/no, n (%) 37 (39)/59 (61)
Pathological differentiation, high/middle/low, n (%) 24 (25)/35 (36)/37 (39)
MVI, yes/no, n (%) 23 (24)/73 (76)
Technique, resection/ablation, n (%) 56 (58)/40 (42)
Hassab’s surgery, yes/no, n (%) 54 (56)/42 (44)
Blood loss (ml), Median (IQR) 350 (200, 700)
Surgical duration (h), Median (IQR) 4.7 (3.6, 5.8)
Postoperative hospital stay (d), Median (IQR) 14.6 (11.1, 19.6)
Postoperative mortality, n (%) 5 (5)
Varices re-hemorrhage during follow-up, n (%) 25 (26)
Tumor recurrence during follow-up, n (%) 62 (65)
Overall RFS during follow-up (month), Median (IQR) 22.3 (10.5, 48)
1-year RFS, n (%) 67 (70)
2-year RFS, n (%) 46 (48)
3-year RFS, n (%) 31 (36)
5-year RFS, n (%) 18 (22)
OS(month) during follow-up, Median (IQR) 46 (22, 68.4)
1-year OS, n (%) 86 (90)
3-year OS, n (%) 56 (70)
5-year OS, n (%) 34 (49)

Abbreviations: WBC, white blood cell count; HGB, hemoglobin; PLT, platelet count; ALT, alanine transaminase; Tbil, total bilirubin; PTA, Prothrombin activity; MVI, microvascular invasion; RFS, recurrence-free survival; OS, overall survival.